Comprehensive in Vitro Characterization of the LSD1 Small Molecule Inhibitor Class in Oncology

250 views | Jan 05 2022

Natalia Sacilotto et al. highlighted significant differences in potency and selectivity among the clinical compounds with iadademstat being the most potent and revealed that most of the tool compounds had very low activity and selectivity. [Read the Full Post]

Targeting LSD1 for acute myeloid leukemia (AML) treatment

462 views | Jan 14 2021

Shujing Zhang et al. discussed the main epigenetic drugs targeting LSD1 for AML therapy. [Read the Full Post]